Recently, CGRP, a neuropeptide that is thought to be essential for inducing migraine, has been implicated in the pathogenesis of TMD and cranial hypersensitivity and has been suggested as a target within TMD treatment [33]. The gene discussed is NPS; the disease is migraine disorder.